What is the difference between CJC-1295 (without DAC) and IGF-2?

CJC-1295 (without DAC): CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. IGF-2: Binds IGF-1R and insulin receptor variant A; promotes anabolic signaling in muscle and fat; activates PI3K/Akt/mTOR pathway; different receptor binding profile than IGF-1

Is IGF-2 FDA approved?

IGF-2 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is CJC-1295 (without DAC) administered in research settings?

In research settings, CJC-1295 (without DAC) is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is IGF-2 administered in research settings?

In research settings, IGF-2 is typically administered via the subcutaneous or intramuscular routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›CJC-1295 (without DAC) vs IGF-2

Peptide Comparison

CJC-1295 (without DAC) vs IGF-2

Name: CJC-1295 (without DAC) vs IGF-2 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are GH / IGF Axis peptides.

CJC-1295 (without DAC)

CJC 1295

Fat LossResearch Only

Half-life: ~30 minutes

454 providers listed

Full CJC-1295 (without DAC) profile →

IGF-2

Insulin-like Growth Factor 2

PerformanceNot EvaluatedResearch Only

Half-life: ~10-20 minutes

No providers listed yet

Full IGF-2 profile →

Bottom line

CJC-1295 (without DAC) carries stronger published evidence (RCT, 3 key studies) than IGF-2 (Case series, 6); both are research compounds.

Quick Verdict

CJC-1295 (without DAC)

Half-life

~30 minutes

IGF-2

Half-life

~10-20 minutes

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	CJC-1295 (without DAC)
Less frequent dosing (longer half-life)	CJC-1295 (without DAC)
More provider options (454 vs 0)	CJC-1295 (without DAC)

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

CJC-1295 (without DAC)

IGF-2

Mechanism Family

GH / IGF Axis

Half-life

~30 minutes

~10-20 minutes

FDA Status

nomination withdrawn

not evaluated

Admin Routes

subcutaneous

subcutaneous, intramuscular

Availability

Research Only

Providers

454 listed

None listed

Avail. Notes

GHRH analog — the truncated 1-29 form (Mod GRF 1-29), WITHOUT the Drug Affinity Complex (DAC). No FDA approval; not on the FDA 503A bulks list. WADA prohibited (S2) as a growth-hormone-releasing factor. Sold as a research chemical only.

Endogenous growth factor. No FDA-approved exogenous IGF-2 drug product. No NDA or IND for IGF-2 as primary active ingredient. Research use only.

Research Evidence

CJC-1295 (without DAC)

RCT · 3 key studies · most recent 2026

IGF-2

Case series · 6 key studies · most recent 2026

Research Citations

CJC-1295 (without DAC)

RCT1997 · Journal of Clinical Endocrinology and Metabolism

Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)…

RCT1997 · Journal of Clinical Endocrinology and Metabolism

Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune syst…

Review2026 · JBJS Rev

Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Imp…

IGF-2

Case series2026 · Endocrinol Diabetes Metab Case Rep

IGF-2-mediated hypoglycemia in a patient with a phyllodes tumor of the breast: a rare presentation of non-isl…

In vitro2026 · Atherosclerosis

Proteomics and ex vivo plaque culture identify the insulin-like growth factor axis as a potential regulator o…

In vitro2011 · Molecular Endocrinology

TGF-β inhibits muscle differentiation by blocking autocrine signaling pathways initiated by IGF-II

Animal2003 · Journal of Biological Chemistry

Autocrine growth factor signaling by insulin-like growth factor-II mediates MyoD-stimulated myocyte maturation

+2 more

About CJC-1295 (without DAC)

CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Lacking the Drug Affinity Complex, it is not albumin-bound and clears within roughly half an hour, producing discrete GH pulses rather than the sustained elevation of the DAC form.

Research Areas

GH and IGF-1 elevationsustained GHRH receptor agonismbody composition supportrecovery enhancementGH axis restoration

About IGF-2

Binds IGF-1R and insulin receptor variant A; promotes anabolic signaling in muscle and fat; activates PI3K/Akt/mTOR pathway; different receptor binding profile than IGF-1

Research Areas

muscle growthfat metabolismtissue developmentrecovery

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

CJC-1295 (without DAC)

Warnings & Cautions

Active malignancy — caution (GH/IGF-1 is mitogenic)Pregnancy — cautionKnown hypersensitivityGlucose intolerance / insulin resistance

Class-based (investigational)

Suggested Monitoring

IGF-1Fasting glucoseHbA1cInsulin

Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.

Regulatory Notes

global — WADA

This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.

source

IGF-2

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Used Together?

CJC-1295 (without DAC)

Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.

Price (per mg)

CJC-1295 (without DAC)

$8.20/mg

$7.07 – $11.29 range

42 vendors

View price index →Find providers →

IGF-2

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

CJC-1295 (without DAC)

454 listed

Browse directory →

Providers offering

IGF-2

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More GH / IGF Axis Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). CJC-1295 (without DAC) vs IGF-2 — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/cjc-1295/igf-2

https://peptidebase.io/peptides/compare/cjc-1295/igf-2 Methodology License Download JSON Download CSV